6th Annual Gene Therapy Immunogenicity Summit

6th Annual Gene Therapy Immunogenicity Summit is organized by Hanson Wade and will be held from Jun 03 - 05, 2025 at Hilton Boston Back Bay, Boston, Massachusetts, United States of America.

Description:
Immunogenicity remains a huge bottleneck for viralbased gene therapy drug developers, limiting the size of dose, repeat dosing and patient recruitment. It’s critical to unite as a community to delve into the current mitigation approaches and share translational data to better predict, monitor and reduce immune responses to AAV and other gene therapy modalities. The 6th Annual Gene Therapy Immunogenicity Summit is the industry’s leading forum dedicated to addressing these challenges head-on, enabling you to learn from those in the clinic to inform your viral vector translational strategy. Uniting VPs, Directors and Scientists of Translation, Preclinical, Non-Clinical and Clinical; this multi-function forum provides an intimate learning and networking opportunity to upskill your team and directly influence your trial strategy and regulatory submission. Bringing together leading minds from biotech, pharma and academia, this year’s summit will explore key advancements across:

• Identifying clinically impactful strategies for combination approaches including navigating complement activation and antibody removal strategies.
• Strategic approaches to enable repeat dosing and expand patient eligibility.
• Regulatory experience to understand what is needed from IND through to clinical development, pinpointing tangible information to identify safety risks and avoid common pitfalls.
• Patient selection criteria and enhanced companion diagnostics to predict risks and balance the benefit/ risk ratio for patients.
• Future considerations for novel vectors with next generation capsid design to overcome current AAV bottlenecks and optimize efficacy and safety.
• Managing immunogenicity across different disease areas to understand any parallels and optimize delivery through different administration routes

The future of the gene therapy industry hinges on mitigating the immunogenicity challenge to develop safe, effective gene therapies. Now is the time to share and assess data from gene therapy leaders to inform your translational strategy for next generation gene therapy trials, to make viral-based treatments safer and more efficacious.